Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, estradiol at higher concentrations inhibited the growth of cashmere goat hair follicles, suggesting a dose-dependent effect on follicle morphology and growth.

This study found that spironolactone effectively reduced hair growth in hirsute women over 12 months and was generally well tolerated.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This study found that treatment with cyproterone acetate and ethinylestradiol in hirsute women reduced testosterone and androstenedione levels, decreased hair growth, and increased cortisol levels without changing catecholamine excretion.

Norplant implants lower some androgen levels but don't significantly change sexual function.

This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

This study concluded that two exemestane preparations are bioequivalent, using a high-performance liquid chromatographic mass spectrometric method to measure concentrations in human plasma.

This article reviews the diverse clinical applications of oral contraceptives beyond birth control, suggesting their effectiveness in treating various female health disorders and conditions.

This review discusses the physiological basis, history, and current development of male hormonal contraception, highlighting its potential risks and benefits, but reports no new research findings.

Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.

This study found that while Sudanese women had good awareness of hormonal contraceptives, they lacked knowledge about emergency contraceptives and non-family planning benefits, with side effects like hair loss influencing their attitudes.

This study found that treatment with cyproterone acetate and estradiol improved emotional well-being and acceptance of being viewed among women with hirsutism, with no significant differences between oral and transdermal estradiol groups.

In this study, overweight women with polycystic ovarian syndrome who took evening primrose oil for 10 weeks experienced significant reductions in BMI, LDL, and total cholesterol levels, alongside hormonal changes such as decreased LH, FSH, and testosterone levels, and increased estrogen.

This article discusses the androgenicity of progestins used in hormonal contraceptives and its potential impact on female pattern hair loss, but reports no new clinical findings.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.

This study observed that thyroid and hormone treatments did not resolve postpartum alopecia in a small patient group, and most cases may naturally revert to normal.

The researchers reported that low-dose methotrexate, in combination with surgical dilatation and local treatments, may improve symptoms in patients with severe stenosing vulvovaginal lichen planus.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

This study suggests that combination drug therapy with spironolactone and either oral contraceptives or dexamethasone effectively manages unresponsive hirsutism, with eight of nine patients achieving satisfactory clinical responses.

The researchers reported finding 53 therapeutic and skincare products for hirsutism and hypertrichosis in Polish pharmacies and drugstores, identifying dienogest and cyproterone acetate as common active ingredients for hirsutism. They noted promising new treatments include eflornithine, acyclovir, licorice, and vitamin D.

In this study, Buserelin nasal spray significantly reduced hirsutism scores and suppressed ovarian steroid secretion in women with non-adrenal hirsutism over six months, with effects lasting post-treatment.

This review reported that spironolactone, used off-label, is an effective and safe treatment option for adult women with acne, presenting fewer adverse reactions compared to common treatments like antimicrobials, which carry the risk of microbial resistance.

In this study, low-dose spironolactone effectively reduced hirsutism in women and stopped hair loss in one woman with alopecia areata, without significant side effects over 12 menstrual cycles.

Estrogen is not recommended for menopausal hair loss due to insufficient evidence.

This study found that women with PCOS who had a higher serum estrone-to-estradiol ratio were more likely to exhibit higher fasting insulin and postprandial glucose levels, even after adjusting for BMI and waist-to-hip ratio.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.